Skip to main content
Erschienen in: American Journal of Cardiovascular Drugs 1/2011

01.02.2011 | Review Article

The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology

verfasst von: Prof. Stefano Taddei, Rosa Maria Bruno, Lorenzo Ghiadoni

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Control of cardiovascular (CV) risk factors, particularly hypertension, is still unsatisfactory, resulting in excess CV morbidity and mortality worldwide. CV risk is linearly associated with an increase in blood pressure (BP) values, and clinical studies have clearly demonstrated that BP lowering represents the most effective means of preventing CV events. However, while BP reduction is a fairly easy target, BP normalization is much more difficult to achieve, and adequate BP control (<140/90 mmHg) is attained only in a small percentage of the hypertensive population.
One of the main reasons for the lack of efficacy of antihypertensive pharmacological treatment is that very often drugs are not administered at the correct dosage. In this review, we discuss the importance of using clinical pharmacology to guide treatment of hypertension.
Controlled clinical trials, including HOPE, EUROPA, and CONSENSUS, are used to guide prescribing decisions. Unfortunately, the results obtained in pivotal studies such as these have been obtained using drug dosages much higher than those usually used in clinical practice. The prescription of a drug for the treatment of hypertension should take into consideration the potency of the drug, i.e. the degree of BP reduction required, and the duration of action of the drug, i.e. the need to cover the dosing interval (possibly 24 hours) in a homogeneous way.
This is especially the case for angiotensin-converting enzyme (ACE) inhibitors, compounds characterized by a flat dose-response curve. The significance of this flat dose-response curve is that a low dose of an ACE inhibitor has the same potency as a high dose but a shorter duration of action. If a low dosage is administered to a hypertensive patient it causes BP fluctuations, which have been associated with negative CV outcomes.
In contrast, other drug classes, including calcium channel antagonists, diuretics, and b-adrenoceptor antagonists, can be used at different dosages in order to modulate their hemodynamic effects.
Thus, it is important to be aware of the clinical pharmacology of antihypertensive drugs in order to choose not only the class or the molecule best suited to the clinical characteristics of the patient, but also the correct dosages to ensure effective and homogeneous 24-hour BP reduction.
Literatur
1.
Zurück zum Zitat Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747–57.PubMedCrossRef Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747–57.PubMedCrossRef
2.
Zurück zum Zitat Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–40.PubMedCrossRef Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–40.PubMedCrossRef
3.
Zurück zum Zitat Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347–60.PubMedCrossRef Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347–60.PubMedCrossRef
4.
Zurück zum Zitat Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13.PubMedCrossRef Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13.PubMedCrossRef
5.
Zurück zum Zitat Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35.PubMedCrossRef Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35.PubMedCrossRef
6.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87.PubMedCrossRef Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87.PubMedCrossRef
7.
Zurück zum Zitat Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121–58.PubMedCrossRef Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121–58.PubMedCrossRef
8.
Zurück zum Zitat Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–23.PubMed Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–23.PubMed
9.
Zurück zum Zitat Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22(12): 2387–96.PubMedCrossRef Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22(12): 2387–96.PubMedCrossRef
10.
Zurück zum Zitat Ezzati M, Oza S, Danaei G, et al. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117(7): 905–14.PubMedCrossRef Ezzati M, Oza S, Danaei G, et al. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117(7): 905–14.PubMedCrossRef
11.
Zurück zum Zitat Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20(8): 1461–4.PubMedCrossRef Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20(8): 1461–4.PubMedCrossRef
12.
Zurück zum Zitat Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009; 11(3): 190–6.PubMedCrossRef Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009; 11(3): 190–6.PubMedCrossRef
13.
Zurück zum Zitat Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403–19.PubMedCrossRef Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403–19.PubMedCrossRef
14.
Zurück zum Zitat The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35.CrossRef The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35.CrossRef
15.
Zurück zum Zitat Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53.PubMedCrossRef Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53.PubMedCrossRef
16.
Zurück zum Zitat Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.PubMedCrossRef Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.PubMedCrossRef
17.
Zurück zum Zitat Salvetti A, Di Venanzio L, Arrighi P, et al. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors? J Hypertens 1994 Suppl.; 12(8): S91–4; discussion S94–5. Salvetti A, Di Venanzio L, Arrighi P, et al. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors? J Hypertens 1994 Suppl.; 12(8): S91–4; discussion S94–5.
18.
Zurück zum Zitat Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5(1): 93–8.PubMedCrossRef Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5(1): 93–8.PubMedCrossRef
19.
Zurück zum Zitat Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11(10): 1133–7.PubMedCrossRef Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11(10): 1133–7.PubMedCrossRef
20.
Zurück zum Zitat Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225(2): 101–5.PubMedCrossRef Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225(2): 101–5.PubMedCrossRef
21.
Zurück zum Zitat Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43(1): 4–9.PubMedCrossRef Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43(1): 4–9.PubMedCrossRef
22.
Zurück zum Zitat Elliott HL, Meredith PA, Vincent J, et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986; 21 Suppl. 1: 27S–31S.PubMedCrossRef Elliott HL, Meredith PA, Vincent J, et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986; 21 Suppl. 1: 27S–31S.PubMedCrossRef
23.
Zurück zum Zitat Salvetti A, Di Venanzio L. Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S31–4.PubMedCrossRef Salvetti A, Di Venanzio L. Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S31–4.PubMedCrossRef
24.
Zurück zum Zitat Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S–29S.PubMedCrossRef Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S–29S.PubMedCrossRef
25.
Zurück zum Zitat Smith DH. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs 2007; 7(5): 347–56.PubMedCrossRef Smith DH. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs 2007; 7(5): 347–56.PubMedCrossRef
26.
Zurück zum Zitat Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008; 29(14): 1739–52.PubMedCrossRef Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008; 29(14): 1739–52.PubMedCrossRef
27.
Zurück zum Zitat Drugs.com: drug information online. Enalapril [online]. Available from URL: http://www.drugs.com/pro/enalapril-tablets.html [Accessed 2010 Nov 1]. Drugs.com: drug information online. Enalapril [online]. Available from URL: http://​www.​drugs.​com/​pro/​enalapril-tablets.​html [Accessed 2010 Nov 1].
28.
Zurück zum Zitat Drugs.com: drug information online. Ramipril [online]. Available from URL: http://www.drugs.com/pro/ramipril.html [Accessed 2010 Nov 1]. Drugs.com: drug information online. Ramipril [online]. Available from URL: http://​www.​drugs.​com/​pro/​ramipril.​html [Accessed 2010 Nov 1].
29.
Zurück zum Zitat Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18(9): 599–606.PubMedCrossRef Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18(9): 599–606.PubMedCrossRef
30.
Zurück zum Zitat Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group? J Hypertens 1997; 15(12 Pt 1): 1511–8.PubMedCrossRef Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group? J Hypertens 1997; 15(12 Pt 1): 1511–8.PubMedCrossRef
31.
Zurück zum Zitat Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S52–5.PubMedCrossRef Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S52–5.PubMedCrossRef
32.
Zurück zum Zitat Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24(1): 3–10.PubMedCrossRef Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24(1): 3–10.PubMedCrossRef
33.
Zurück zum Zitat Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.PubMedCrossRef Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.PubMedCrossRef
34.
Zurück zum Zitat Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28.PubMedCrossRef Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28.PubMedCrossRef
35.
Zurück zum Zitat Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987; 5(4): S139–42.PubMedCrossRef Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987; 5(4): S139–42.PubMedCrossRef
36.
Zurück zum Zitat Chatzikyrkou C, Haller H, Menne J. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril? Expert Opin Pharmacother 2009; 10(11): 1833–40.PubMedCrossRef Chatzikyrkou C, Haller H, Menne J. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril? Expert Opin Pharmacother 2009; 10(11): 1833–40.PubMedCrossRef
37.
Zurück zum Zitat Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8(1): 45–50.PubMedCrossRef Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8(1): 45–50.PubMedCrossRef
Metadaten
Titel
The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology
verfasst von
Prof. Stefano Taddei
Rosa Maria Bruno
Lorenzo Ghiadoni
Publikationsdatum
01.02.2011
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 1/2011
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/11586670-000000000-00000

Weitere Artikel der Ausgabe 1/2011

American Journal of Cardiovascular Drugs 1/2011 Zur Ausgabe

Adis Drug Evaluation

Dabigatran Etexilate

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.